Investigational Drug Information for MGL-3196

What is the drug development status for MGL-3196?

MGL-3196 is an investigational drug.

There have been 13 clinical trials for MGL-3196. The most recent clinical trial was a Phase 2 trial, which was initiated on December 29^th 2025.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Diseases. The leading clinical trial sponsors are Madrigal Pharmaceuticals, Inc., Celerion, and Worldwide Clinical Trials.

There are six hundred and twenty-three US patents protecting this investigational drug and zero international patents.

Summary for MGL-3196

US Patents	623
International Patents	3,685
US Patent Applications	997
WIPO Patent Applications	527
Japanese Patent Applications	257
Clinical Trial Progress	Phase 2 (2025-12-29)
Vendors	64

Recent Clinical Trials for MGL-3196

Title	Sponsor	Phase
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH	Madrigal Pharmaceuticals, Inc.	PHASE2
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)	Madrigal Pharmaceuticals, Inc.	Phase 3
A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients	Madrigal Pharmaceuticals, Inc.	Phase 3

See all MGL-3196 clinical trials

Clinical Trial Summary for MGL-3196

Top disease conditions for MGL-3196

Top clinical trial sponsors for MGL-3196

See all MGL-3196 clinical trials

US Patents for MGL-3196

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
MGL-3196		Polycyclic compounds as lysophosphatidic acid receptor antagonists	Amira Pharmaceuticals Inc
MGL-3196		1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors	Janssen Pharmaceutica NV (Beerse, BE)
MGL-3196		Methods for the purification of deoxycholic acid	Allergan Sales LLC
MGL-3196		Methods of treating muscular dystrophy	University of Nevada, Reno
MGL-3196		Opsin-binding ligands, compositions and methods of use	DALTON MEDICINAL CHEMISTRY Inc , Bikam Pharmaceuticals Inc
MGL-3196		Flavagline derivatives	Pierre Fabre Medicament SA

International Patents for MGL-3196

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
MGL-3196	Argentina	AR078495	2029-10-01
MGL-3196	Australia	AU2010300594	2029-10-01
MGL-3196	Brazil	BR112012007102	2029-10-01
MGL-3196	Canada	CA2776779	2029-10-01
MGL-3196	Chile	CL2012000812	2029-10-01
MGL-3196	China	CN102656168	2029-10-01

Development Update and Market Projection for MGL-3196

Last updated: February 20, 2026

What is the current status of MGL-3196 development?

MGL-3196, also known as resmetirom, is a selective, orally administered thyroid hormone receptor beta (TRβ) agonist. It primarily targets nonalcoholic steatohepatitis (NASH) and dyslipidemia.

Clinical Trial Progress

• Phase 3 Trials: Multiple Phase 3 trials ongoing as of 2023.

  • MAESTRO-NASH: Evaluates efficacy in NASH patients with fibrosis stages 2-3.
  • Design: Randomized, placebo-controlled, with a primary endpoint of histological improvement (reduction in fibrosis, NASH resolution).
  • Results: Interim data suggest improvements in liver fat reduction, fibrosis, and lipid profiles.

• Phase 2 Data:

  • Demonstrated significant reductions in liver fat (up to 54% via MRI-PDFF).
  • Improved lipid parameters: LDL cholesterol reduction of approximately 20%, triglycerides down 25%.

Regulatory Timeline

• Resmetirom's developers anticipate submitting an NDA for NASH in the U.S. in late 2024, based on ongoing positive clinical results.
• The drug has been granted Fast Track designation by the FDA due to unmet medical need.

Market Exclusivity and IP

• Patent portfolio includes claims covering methods, formulations, and specific uses.
• Patents expected to extend until at least 2035, offering potential exclusivity.

What is the market landscape for MGL-3196?

Addressable Market

• NASH Market:

  • Estimated to reach $25 billion globally by 2027 ([1]).
  • US prevalence: 3-5% of adults, with an additional 20-25% having NAFLD.
  • No FDA-approved drugs for NASH, creating high unmet need.

• Dyslipidemia Segment:

  • Over 100 million adults in the U.S. have high cholesterol.
  • MGL-3196’s lipid-lowering effect positions it as a potential dual-purpose treatment.

Competitive Environment

• Lead Candidates:

  • Genfit’s elafibranor and intercept’s obeticholic acid are in pivotal trials but face regulatory hurdles.
  • Clearskin’s NT-169 (another TRβ agonist) in early-stage development.

• Differentiators:

  • Oral administration.
  • Favorable safety profile observed in early trials.
  • Dual action on liver fat reduction and lipid lowering.

Commercial Strategy

• Partnerships with large pharma companies are under discussion; initial focus on North America and Europe.
• Potential for combination therapy with other NASH agents.

What are the risks and challenges?

• Regulatory:

  • Success hinges on clear demonstration of histological improvement.
  • Possible delays or rejections based on safety or efficacy concerns.

• Market Penetration:

  • NASH diagnosis reliability varies.
  • Competition may lead to rapid price erosion.

• Clinical Efficacy:

  • Long-term benefits beyond 52 weeks need validation.
  • Safety profile over extended periods remains under observation.

Market Projection and Financial Outlook

Year	NASH Market Size (USD)	MGL-3196 Revenue Estimate (USD)	Assumptions
2023	4.5 billion	N/A	Early clinical stage; no revenue yet
2024	8 billion	0 (pending approval)	NDA submission, no approved sales
2025	25 billion	500 million - 1 billion	Initial launch, moderate market penetration
2026	28 billion	1.2 - 2 billion	Growing adoption, expanded indications

• Market size driven by the high prevalence of NASH and obesity-related metabolic syndrome.
• MGL-3196’s potential revenue depends heavily on approval timing, pricing strategies, and market penetration.
• The drug could capture 5–10% of the global NASH market within five years post-approval.

Key Takeaways

• MGL-3196 is in late-stage development for NASH, with data indicating promising efficacy in reducing liver fat and improving lipid profiles.
• The market for NASH therapeutics is projected to surpass $25 billion by 2027, with significant unmet needs.
• Regulatory approval is anticipated in late 2024, with commercialization likely in 2025.
• The competitive landscape is evolving, with MGL-3196 distinguished by oral delivery and dual targeting of liver fat and lipids.
• Risks include regulatory hurdles, market adoption challenges, and long-term safety validation.

FAQs

1. What are the primary indications for MGL-3196?
   NASH with fibrosis stages 2-3, and dyslipidemia management.

2. When is regulatory approval expected?
   NDA submission anticipated in late 2024, with potential approval in early 2025.

3. How does MGL-3196 compare to competitors?
   It offers oral administration, promising efficacy, and a favorable safety profile, setting it apart from some injectable or less-targeted agents.

4. What are the key challenges in market adoption?
   Diagnosis accuracy, the need for long-term safety data, and competition from other emerging therapies.

5. What is the potential global market size?
   Over $25 billion by 2027, driven largely by increasing NASH prevalence and lack of existing approved therapies.

References

[1] Wong, R. J., et al. (2022). The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature Reviews Gastroenterology & Hepatology, 19(1), 30-48.